Overview

A class action lawsuit has been filed against Novo Nordisk A/S (“Novo” or the “Company”) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws. The Company’s common stock traded on the New York Stock Exchange (the “NYSE”) under the symbol “NVO.”

The Novo class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Novo securities between May 7, 2025, to July 28, 2025, both dates inclusive (the “Class Period”).

Novo is a healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally. The Company operates in two segments, diabetes and obesity on one arm, and rare diseases on the other. Novo is internationally headquartered outside of Copenhagen, Denmark, while its United States headquarters are in Plainsboro, New Jersey.

The Novo class action lawsuit alleges that Defendants provided investors with material information concerning Novo’s expected sales and revenue growth for the fiscal year 2025. Defendants’ statements included, among other things, confidence in the Company’s ability to continue to grow GLP-1 sales by capitalizing on the significant size, low penetration, and overall potential of the GLP-1 market, including Novo’s ability to capitalize on patients who would purportedly be no longer able to utilize their preferred compounded GLP-1 alternatives.

Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo’s growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo’s branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo’s capability to penetrate said markets to achieve continued growth. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Novo’s securities at artificially inflated prices.

*          *          *

If you purchased or otherwise acquired Novo securities between May 7, 2025, to July 28, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the Novo class action lawsuit is September 30, 2025.